Comparing secukinumab and upadacitinib in axial spondyloarthritis after a TNF inhibitor stopped working
Compares secukinumab with upadacitinib in adults with axial spondyloarthritis after a TNF inhibitor failed.
Plain-language title generated from the registry record
Registry title: A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
Key facts
- Where
- Houston, United StatesSee the site
- Phase
- Phase 4
Where in United States
- The University of Texas Health Science Center at HoustonHouston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Texas Health Science Center, Houston
- Trial code
- NCT07770646
- Record updated
- 14 October 2026
- Original description
The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKiRead full original descriptionShow less
A Pragmatic Randomized Pilot Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi
Inclusion: fulfill ASAS classification criteria for axSpA and/or modified New York classification criteria for AS; Active axSpA (ASDAS ≥ 2.1 and/or BASDAI ≥ 4); Failure of or intolerance to ≥1 TNF; Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication; Ability to provide informed consent.
Exclusion: Previously received an IL-17i or JAKi; Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy; Active infection requiring antimicrobials; Contraindications to either treatment arm:; Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis; Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN); History of stroke, heart attack, or blood clots (venous or arterial); Cirrhosis; End-stage renal disease (GFR <15) or dialysis; Human Immunodeficiency Virus (HIV) positive; Pregnant or lactating.